NAMS Menopause Certification Review Guide 2026/2027 | High-Yield
Practice Questions with Rationales
Question 1
What is the clinical definition used to establish a retrospective diagnosis
of natural menopause?
• A. Six consecutive months of amenorrhea accompanied by
elevated estradiol levels
• B. Twelve consecutive months of spontaneous amenorrhea
without other pathological or physiological cause
• C. Two consecutive years of irregular cycles occurring after age 45
• D. A single serum follicle-stimulating hormone level exceeding 40
IU/L
Correct Answer: B. Twelve consecutive months of spontaneous
amenorrhea without other pathological or physiological cause
Detailed Rationale: Natural menopause is diagnosed retrospectively
after a woman has experienced 12 consecutive months of absolute
amenorrhea in the absence of other medical, surgical, or physiological
explanations.
Question 2
Which hypothalamic neural pathway undergoes hypertrophy and
hyperactivation during estrogen withdrawal, triggering vasomotor
symptoms?
• A. Dopaminergic substantia nigra pathway
, • B. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
• C. Cholinergic basal nucleus of Meynert
• D. Serotonergic raphe nuclei projections exclusively
Correct Answer: B. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Detailed Rationale: KNDy neurons in the infundibular nucleus of the
hypothalamus control thermoregulation. Estrogen deficiency leads to
hypertrophy of these neurons, narrowing the thermoneutral zone and
causing inappropriate heat dissipation responses (hot flashes).
Question 3
When selecting systemic menopausal hormone therapy for a patient
with risk factors for thrombosis, why is transdermal 17-beta estradiol
preferred over oral conjugated equine estrogens?
• A. Transdermal estradiol bypasses hepatic first-pass metabolism,
avoiding adverse alterations in coagulation factors and lowering
VTE risk.
• B. Transdermal patches directly stimulate hepatic synthesis of
antithrombin III.
• C. Oral estrogen permanently deactivates all circulating platelets.
• D. Transdermal estradiol contains active anticoagulant proteins.
Correct Answer: A. Transdermal estradiol bypasses hepatic first-pass
metabolism, avoiding adverse alterations in coagulation factors and
lowering VTE risk.
Detailed Rationale: Oral estrogens undergo first-pass liver metabolism,
which increases hepatic production of clotting factors and inflammatory
,markers, elevating venous thromboembolism risk. Transdermal
administration avoids this hepatic impact.
Question 4
What is the recommended first-line treatment for a postmenopausal
woman presenting with localized genitourinary syndrome of
menopause (GSM) characterized by vaginal dryness and dyspareunia
without systemic symptoms?
• A. High-dose oral conjugated equine estrogens
• B. Low-dose vaginal estrogen therapy or non-hormonal
moisturizers/lubricants
• C. Systemic oral selective estrogen receptor modulators
• D. Intramuscular testosterone depot injections
Correct Answer: B. Low-dose vaginal estrogen therapy or non-hormonal
moisturizers/lubricants
Detailed Rationale: When symptoms are restricted to the genitourinary
tract, local low-dose vaginal estrogen or regular non-hormonal
moisturizers provide targeted tissue relief with minimal systemic
absorption.
Question 5
According to clinical criteria, what defines premature ovarian
insufficiency (POI)?
• A. Cessation of menses for 12 consecutive months before the age
of 40 with elevated menopausal-range FSH levels
• B. Irregular cycles occurring exclusively between ages 45 and 50
, • C. Permanent surgical removal of the uterus while retaining both
ovaries
• D. Complete absence of secondary sex characteristics starting at
age 18 with normal hormone levels
Correct Answer: A. Cessation of menses for 12 consecutive months
before the age of 40 with elevated menopausal-range FSH levels
Detailed Rationale: POI is diagnosed when a woman under age 40
experiences oligo-amenorrhea for at least 4 to 6 months coupled with
elevated gonadotropins (FSH) in the menopausal range on two
occasions at least one month apart.
Question 6
Fezolinetant is a non-hormonal pharmaceutical agent approved for
managing moderate-to-severe vasomotor symptoms. What is its
mechanism of action?
• A. Selective serotonin reuptake inhibition in cortical synapses
• B. Neurokinin 3 (NK3) receptor antagonism in the hypothalamus
• C. Gamma-aminobutyric acid type A receptor agonism
• D. Alpha-2 adrenergic receptor stimulation in vascular walls
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonism in the
hypothalamus
Detailed Rationale: Fezolinetant is a selective NK3 receptor antagonist
that blocks neurokinin B signaling within the hypothalamic
thermoregulatory center, effectively calming hyperactive KNDy neurons
and reducing hot flashes.
Practice Questions with Rationales
Question 1
What is the clinical definition used to establish a retrospective diagnosis
of natural menopause?
• A. Six consecutive months of amenorrhea accompanied by
elevated estradiol levels
• B. Twelve consecutive months of spontaneous amenorrhea
without other pathological or physiological cause
• C. Two consecutive years of irregular cycles occurring after age 45
• D. A single serum follicle-stimulating hormone level exceeding 40
IU/L
Correct Answer: B. Twelve consecutive months of spontaneous
amenorrhea without other pathological or physiological cause
Detailed Rationale: Natural menopause is diagnosed retrospectively
after a woman has experienced 12 consecutive months of absolute
amenorrhea in the absence of other medical, surgical, or physiological
explanations.
Question 2
Which hypothalamic neural pathway undergoes hypertrophy and
hyperactivation during estrogen withdrawal, triggering vasomotor
symptoms?
• A. Dopaminergic substantia nigra pathway
, • B. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
• C. Cholinergic basal nucleus of Meynert
• D. Serotonergic raphe nuclei projections exclusively
Correct Answer: B. Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
Detailed Rationale: KNDy neurons in the infundibular nucleus of the
hypothalamus control thermoregulation. Estrogen deficiency leads to
hypertrophy of these neurons, narrowing the thermoneutral zone and
causing inappropriate heat dissipation responses (hot flashes).
Question 3
When selecting systemic menopausal hormone therapy for a patient
with risk factors for thrombosis, why is transdermal 17-beta estradiol
preferred over oral conjugated equine estrogens?
• A. Transdermal estradiol bypasses hepatic first-pass metabolism,
avoiding adverse alterations in coagulation factors and lowering
VTE risk.
• B. Transdermal patches directly stimulate hepatic synthesis of
antithrombin III.
• C. Oral estrogen permanently deactivates all circulating platelets.
• D. Transdermal estradiol contains active anticoagulant proteins.
Correct Answer: A. Transdermal estradiol bypasses hepatic first-pass
metabolism, avoiding adverse alterations in coagulation factors and
lowering VTE risk.
Detailed Rationale: Oral estrogens undergo first-pass liver metabolism,
which increases hepatic production of clotting factors and inflammatory
,markers, elevating venous thromboembolism risk. Transdermal
administration avoids this hepatic impact.
Question 4
What is the recommended first-line treatment for a postmenopausal
woman presenting with localized genitourinary syndrome of
menopause (GSM) characterized by vaginal dryness and dyspareunia
without systemic symptoms?
• A. High-dose oral conjugated equine estrogens
• B. Low-dose vaginal estrogen therapy or non-hormonal
moisturizers/lubricants
• C. Systemic oral selective estrogen receptor modulators
• D. Intramuscular testosterone depot injections
Correct Answer: B. Low-dose vaginal estrogen therapy or non-hormonal
moisturizers/lubricants
Detailed Rationale: When symptoms are restricted to the genitourinary
tract, local low-dose vaginal estrogen or regular non-hormonal
moisturizers provide targeted tissue relief with minimal systemic
absorption.
Question 5
According to clinical criteria, what defines premature ovarian
insufficiency (POI)?
• A. Cessation of menses for 12 consecutive months before the age
of 40 with elevated menopausal-range FSH levels
• B. Irregular cycles occurring exclusively between ages 45 and 50
, • C. Permanent surgical removal of the uterus while retaining both
ovaries
• D. Complete absence of secondary sex characteristics starting at
age 18 with normal hormone levels
Correct Answer: A. Cessation of menses for 12 consecutive months
before the age of 40 with elevated menopausal-range FSH levels
Detailed Rationale: POI is diagnosed when a woman under age 40
experiences oligo-amenorrhea for at least 4 to 6 months coupled with
elevated gonadotropins (FSH) in the menopausal range on two
occasions at least one month apart.
Question 6
Fezolinetant is a non-hormonal pharmaceutical agent approved for
managing moderate-to-severe vasomotor symptoms. What is its
mechanism of action?
• A. Selective serotonin reuptake inhibition in cortical synapses
• B. Neurokinin 3 (NK3) receptor antagonism in the hypothalamus
• C. Gamma-aminobutyric acid type A receptor agonism
• D. Alpha-2 adrenergic receptor stimulation in vascular walls
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonism in the
hypothalamus
Detailed Rationale: Fezolinetant is a selective NK3 receptor antagonist
that blocks neurokinin B signaling within the hypothalamic
thermoregulatory center, effectively calming hyperactive KNDy neurons
and reducing hot flashes.
